---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-075775"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2026-06-18T20:30:36+00:00"
generated_at: "2026-06-18T20:37:44.622809+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# SELLAS stockholders approve 20M share equity plan increase, re-elect directors

## Summary
- Directors Robert Van Nostrand and Jane Wasman re-elected; Van Nostrand 66.5M for, Wasman 65.9M for.
- Ratification of Baker Tilly US as independent auditor for FY2026 approved with 112.1M votes for.
- Amendment to 2023 Equity Plan increasing authorized shares by 20M approved: 42.9M for, 27.3M against.
- Non-binding advisory say-on-pay resolution passed: 52.9M for, 15.9M against.
- Adjournment proposal approved with 90.6M for, 22.2M against.

## SEC filing metadata
- accession: 0001104659-26-075775
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2026-06-18T20:30:36+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465926075775/0001104659-26-075775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000110465926075775/tm2618311d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-075775
- JSON: https://secwatch.observer/filing/0001104659-26-075775.json
- Plain text: https://secwatch.observer/filing/0001104659-26-075775.txt

## Key facts
- Shareholder Votes
  SELLAS Life Sciences Group, Inc. shareholders approved Amendment to 2023 Amended and Restated Equity Incentive Plan to increase shares available by 20,000,000 at the 2026-06-16 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-06-16
  source text: The Company’s stockholders approved an amendment to the Company’s 2023 Amended and Restated Equity Incentive Plan (the “2023 Equity Plan”) to increase the number of shares of common stock available for sale under the 2023 Equity Plan by 20,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000110465926075775/0001104659-26-075775-index.htm
- Shareholder Votes
  SELLAS Life Sciences Group, Inc. shareholders approved Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-16 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-16
  source text: The Company’s stockholders ratified the appointment of Baker Tilly US, LLP (as the successor to Moss Adams LLP) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000110465926075775/0001104659-26-075775-index.htm
- Shareholder Votes
  SELLAS Life Sciences Group, Inc. shareholders approved Adjournment of the Annual Meeting to solicit additional proxies if necessary at the 2026-06-16 meeting.
  - Outcome: passed
  - Meeting: 2026-06-16
  source text: The Company’s stockholders approved an adjournment of the Annual Meeting, if necessary, to solicit additional proxies in favor of proposals 1, 2, 3 and 4.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000110465926075775/0001104659-26-075775-index.htm
- Shareholder Votes
  SELLAS Life Sciences Group, Inc. shareholders approved Election of Class I Directors at the 2026-06-16 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-16
  source text: The Company’s stockholders re-elected each of the following nominees as a Class I director to the Board of the Company to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000110465926075775/0001104659-26-075775-index.htm
- Shareholder Votes
  SELLAS Life Sciences Group, Inc. shareholders approved Non-binding advisory resolution on executive compensation at the 2026-06-16 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-16
  source text: The Company’s stockholders approved the non-binding, advisory resolution on the executive compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000110465926075775/0001104659-26-075775-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.